Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Evofem

Evofem, the startup trying to survive the broken birth-control market, finally sells itself

Aditxt is buying the buzzy but controversial maker of Phexxi, in a deal valued at $100 million.

Fortune · Dec 13, 2023

She spent a decade trying to build better women's health care—now her startup is on the brink of failure

Evofem Biosciences CEO Saundra Pelletier has spent a decade trying to steer her startup through a litany of business challenges.

Fortune · Apr 11, 2023

‘Anything to survive’: How one leader is pushing ahead

The CEO of Evofem Biosciences is managing through a crushing debt load, Nasdaq delisting, and sweeping layoffs.

Fortune · Apr 10, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

U.S. women need better birth control. So why is this contraceptive company 'on life support?'

Evofem Biosciences has prescribed its nonhormonal contraceptive to more than 100,000 women, but is still on the brink of collapse.

Fortune · Apr 5, 2023

Birth control fail: Why American women can’t have better contraceptives in 2023

The rocky history of Evofem and Phexxi illuminates how big insurers and drugmakers are stifling innovation in women’s health.

Fortune · Apr 5, 2023

How Does The Abortion Ban Affect Birth Control Stocks?

The debate over abortion reignited in the US following the Supreme Court’s decision to overturn the landmark 1973 Roe v. Wade ruling that generally protects women’s rights to abortion.

Benzinga · Jul 5, 2022

Why Evofem Biosciences Stock Is Surging Today

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading higher Tuesday after the company announced an agreement with a pharmacy benefit manager.

Benzinga · Jun 28, 2022

Read news from The Economist, FT, and more,
with one subscription

Why Evofem Biosciences Shares Are Getting Hammered Today

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly $26.6 million public offering.

Benzinga · May 20, 2022

Coverage From

People

Joe Biden

69,234 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.